Connecticut 2023 Regular Session

Connecticut House Bill HB06830

Introduced
3/1/23  
Introduced
3/1/23  
Refer
3/1/23  
Refer
3/1/23  
Report Pass
3/16/23  
Refer
3/27/23  
Refer
3/27/23  

Caption

An Act Establishing A Prescription Drug Affordability Advisory Council.

Impact

The bill's establishment of the advisory council is intended to streamline and enhance the state's approach to managing healthcare costs. By involving diverse stakeholders from the healthcare industry, including representatives from labor unions, health insurance, and pharmaceutical companies, the council aims to foster a collaborative environment focused on making prescription drugs more affordable for citizens. The implementation of this council could lead to more informed decisions in policy-making, which would directly impact the economic burden experienced by residents concerning healthcare expenses.

Summary

House Bill 6830 establishes a Prescription Drug Affordability Advisory Council within the Health Care Cabinet of the Office of Health Strategy. This council is tasked with providing recommendations on policy initiatives related to healthcare costs, specifically focusing on cost trends in pharmaceuticals, hospital costs, and billing from healthcare providers. The advisory council aims to address the pressing issue of affordability in prescription medications and provide a framework for reviewing and advising on relevant cost initiatives in the state.

Sentiment

The sentiment surrounding HB 6830 is generally positive among proponents who view it as a proactive step towards addressing the rising costs of prescription drugs. Supporters believe that the establishment of the advisory council will enhance transparency and ensure that the voices of various stakeholders are taken into account in the decision-making process. However, some skepticism exists concerning potential conflicts of interest among council members, especially those who are directly connected to pharmaceutical companies.

Contention

A noteworthy point of contention relates to the composition of the advisory council, specifically the inclusion of representatives from large pharmaceutical manufacturers and the health insurance industry. Critics argue that such representation might lead to recommendations that prioritize the interests of these entities over the affordability and accessibility needs of consumers. The challenge will be ensuring that the council remains focused on the public interest rather than being swayed by the financial motivations of its members.

Companion Bills

No companion bills found.

Previously Filed As

CT SB00008

An Act Concerning Drug Affordability.

CT SB00133

An Act Concerning Regulation Of Prescription Drugs And Related Professions.

CT HB05054

An Act Addressing Health Care Affordability.

CT SB00202

An Act Concerning The Department Of Consumer Protection's Recommendations Regarding Prescription Drug Control.

CT SB00162

An Act Establishing Tax Incentives To Support Prescription Drug Compounding.

CT SB00182

An Act Prohibiting Certain Health Carriers From Requiring Step Therapy For Prescription Drugs Used To Treat A Mental Or Behavioral Health Condition Or A Chronic, Disabling Or Life-threatening Condition.

CT HB05379

An Act Concerning The Duties Of The State Marshals And The Operation Of The State Marshal Commission And The State Marshals Advisory Board.

CT SB00198

An Act Establishing Local Representation On The Connecticut Siting Council For Local Projects.

CT HB05332

An Act Establishing The Interagency Council On Homelessness.

CT SB00142

An Act Establishing A Housing Authority Resident Quality Of Life Improvement Grant Program And A Housing Choice Voucher Task Force.

Similar Bills

CA SB602

Advisory bodies.

CA SB1048

Advisory bodies.

CA AB3239

Advisory bodies.

CA SB335

Nursery Advisory Board.

CA SB997

Local control and accountability plans: parent advisory committee: student advisory committee.

CA AB652

Department of Pesticide Regulation Environmental Justice Advisory Committee.

CA AB382

Whole Child Model program.

CA SB220

Medi-Cal Children’s Health Advisory Panel.